EXCRETORY SYSTEM
KIDNEY
|
Question
[CLICK ON ANY CHOICE TO KNOW THE RIGHT ANSWER]
|
Which SGLT-2 Inhibitor has been FDA approved to preserve eGFR?
|
|
Invokana
|
|
|
Dapagliflozin
|
|
|
Canagliflozin
|
|
|
Jardiance
|
Explanation:
Detailed explanation-1: -Four agents (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin) are FDA-approved for managing adult patients with type 2 diabetes mellitus (DM) to improve blood sugar control adjunct to diet and exercise.
Detailed explanation-2: -Forxiga (dapagliflozin) can now be prescribed to treat adults with chronic kidney disease (CKD), with or without diabetes. To continue enjoying this article, please sign in.
Detailed explanation-3: -On April 30, 2021, the US Food and Drug Administration (FDA) approved the SGLT2 inhibitor dapagliflozin in patients to reduce the risk of adverse kidney and CVD outcomes in patients with CKD who are at risk of progression. FDA approves treatment for chronic kidney disease.
There is 1 question to complete.